With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Non-small cell lung cancer (NSCLC) has been needing one for years. The current graded prognostic assessment is based on outcomes dating back to the 1980s. More recent data (read: from this millennium) on 2186 patients with newly-diagnosed NSCLC brain mets were analyzed with the additional prognostic factors of EGFR and ALK alterations. Remarkably, those with higher (3.5-4.0) Lung-molGPA scores had a median survival approaching 4 years--as compared to 14 months among top-scorers in the current DS-GPA. Now that is a 4.0 worthy of recognition.